Our mission

At HALIX, we are dedicated to empowering biotech companies create life-saving therapeutics and deliver them to those in need, enabled by three key strengths:

  • Infrastructure, skill, and discipline of a seasoned company

  • Speed, innovation, and dynamism of a startup
  • Open, proactive, and agile communication

Over a decade of experience bringing GMP excellence

We are a fast growing, contract development and manufacturing organization (CDMO) focused on mammalian expression systems for the production of viral vectors, viral vector vaccines and recombinant proteins. Located within the Leiden Bio Science Park in the Netherlands, we support our customers develop and bring to market biologics that can be used to treat cancer, COVID-19, influenza, and other life-threatening and infectious diseases.

A solid foundation

Established in 2012 as a spin-off of HAL Allergy one of the top European pharma players in the field of allergy immunotherapy we leverage HAL’s years of industry experience and GMP expertise in the extraction, purification and modification of biologics and benefit from a close corporate structure providing long-term stability.

Agility and entrepreneurial spirit of a startup

At the same time, being a spin off, we fully embrace the agility and entrepreneurial spirit of a startup. Our adaptive mentality allows us to quickly respond to trends and challenges, enabling our partners to bring their therapeutics to market as fast and efficiently as possible.

 

Agility and entrepreneurial spirit of a startup

At the same time, being a venture spin off, we fully embrace the agility and entrepreneurial spirit of a startup. Our adaptive mentality allows us to quickly respond to trends and challenges, enabling our partners to bring their therapeutics to market as fast and efficiently as possible.

Communication as key to succeed your project

We combine ‘single point of contact’ project management with proven and sound processes and procedures. From development to clinical up to commercialization, we provide high quality and flexible CDMO services to biopharmaceutical partners, enabling you to progress through clinical phases in order to enter and supply your markets with the most efficient use of resources.

Our core values

  • null
    Serving bioscience is in our DNA. We understand that when our customers entrust us with their products they are entrusting us with something invaluable, so we take excellent care of it, providing them with the utmost reliability.
  • null
    We are relentless in the creation of life-saving products.
  • null
    We collaborate openly and transparently with our customers, always acting as a trusted partner.
  • null
    We recognize the risks associated with clinical trials and commercialization, so we move fast and embrace change to help our customers navigate these challenges and achieve success.

Stability and long-term focus

HALIX was established as an 100% subsidiary of HAL Allergy Holding B. V., internationally known as HAL Allergy Group. The HAL Allergy Group belongs to the family owned Droege Group AG, an independent advisory and investment company under full family ownership. Together with the Droege Group and the HAL Allergy Group, HALIX has two strong corporate partners ensuring financial stability, opportunity investment,  and a long term focus.